Anaemia management in non-dialysis chronic kidney disease (CKD) patients: A multicentre prospective study in renal clinics

Nephrology Dialysis Transplantation

Volumn 28, Issue 12, 2013, Pages 3035-3045

  Minutolo, Roberto ^a   Locatelli, Francesco ^b   Gallieni, Maurizio ^c   Bonofiglio, Renzo ^d   Fuiano, Giorgio ^e   Oldrizzi, Lamberto ^f   Conte, Giuseppe ^a   De Nicola, Luca ^a   Mangione, Filippo ^g   Esposito, Pasquale ^g   Dal Canton, Antonio ^g  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b A MANZONI HOSPITAL   (Italy)

^c SAN CARLO BORROMEO HOSPITAL   (Italy)

^d Ospedale dell'Annunziata   (Italy)

^e UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^f Section of Onco Hematology   (Italy)

^g FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Anaemia; Chronic kidney disease; ESA; Iron deficiency; Iron therapy

Indexed keywords

ANTIANEMIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TRANSFERRIN;

AGE; AGED; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; IRON DEFICIENCY; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ANAEMIA; CHRONIC KIDNEY DISEASE; ESA; IRON DEFICIENCY; IRON THERAPY;

AGED; ANEMIA; DIETARY SUPPLEMENTS; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMOGLOBINS; HUMANS; IRON; ITALY; MALE; PREVALENCE; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84890059647     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft338     Document Type: Article

References (45)

1. Jones C, Roderick P, Harris S, Rogerson M. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant 2006; 21: 2133-2143
2. El Nahas AM, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331-340
3. US Department of Health and Human Services. Healthy People 2010, 2nd edn. Washington, DC: US Government Printing Office, 2000
4. Tseng CL, Kern EFO, Miller DR et al. Survival benefit of nephrologic care in patients with diabetes mellitus and chronic kidney disease. Arch Intern Med 2008; 168: 55-62
5. De Nicola L, Minutolo R, Chiodini P et al., for the SIN-TABLE CDK Study Group. Prevalence and prognosis of mild anemia in non-dialysis chronic kidney disease: a prospective cohort study in outpatient renal clinics. Am J Nephrol 2010; 32: 533-540
6. De Nicola L, Chiodini P, Zoccali C, for the SIN-TABLE CKD Study Group. Prognosis of CKD patients receiving outpatient nephrology care in Italy. Clin J Am Soc Nephrol 2011; 6: 2421-2428
7. Levin A, Djurdjev O, Duncan J et al. Haemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long-term outcomes. Nephrol Dial Transplant 2006; 21: 370-377
8. Astor BC, Coresh J, Heiss G et al. Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2006; 151: 492-500
9. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006; 69: 560-564
10. Stevens PE, Schernthaner G, Raptis S et al. Characteristics, cardiovascular comorbidity and medicines management in patients with type 2 diabetes and CKD: results of the IRIDIEM Study. Kidney Blood Press Res 2010; 33: 119-128
11. Martínez-Castelao A, Górriz JL, Portolés JM et al. Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study. BMC Nephrol 2011; 12: 53
12. Lawler EV, Gagnon DR, Fink J et al. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration. Nephrol Dial Transplant 2010; 25: 2237-2244
13. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2: 279-335
14. Pfeffer MA, Burdmann EA, Chen CY et al., for TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
15. Singh AK, Szczech L, Tang KL et al., for CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Eng J Med 2006; 335: 2085-2098
16. Drueke TB, Locatelli F, Clyne N et al., for CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Eng J Med 2006; 335: 2071-2084
17. Freburger JK, Ng LJ, Bradbury BD et al. Changing patterns of anemia management in US hemodialysis patients. Am J Med 2012; 125: 906-914
18. Seliger S, Fox KM, Gandra SR et al. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study. Clin J Am Soc Nephrol 2010; 5: 882-888
19. Fox KM, Yee J, Cong Z et al. Transfusion burden in non-dialysis chronic kidney disease patients with persistent anemia treated in routine clinical practice: a retrospective observational study. BMC Nephrol 2012; 13: 5
20. Lawler EV, Bradbury BD, Fonda JR et al. Transfusion burden among patients with chronic kidney disease and anemia. Clin J Am Soc Nephrol 2010; 5: 667-672
21. Nordio M, Postorino M, Casino F et al. Standardization criteria to ensure the uniformity of data collection by the Italian Registry of Dialysis and Transplantation. Giorn It Nefrol 2005; 22: 152-158
22. Locatelli F, Covic A, Eckardt KU et al., on behalf of the ERAEDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24: 348-354
23. Valderrabano F, Horl WH, Macdougall IC et al. PRE-dialysis survey on anaemia management. Nephrol Dial Transplant 2003; 18: 89-100
24. Locatelli F, Covic A, Macdougall IC, Wiecek A, ORAMA Study Group. ORAMA: a study to investigate EBPG impact on renal anaemia: design and baseline data. J Nephrol 2008; 21: 592-603
25. Ritz E, Laville M, Bilous RWet al. Anemia Correction in Diabetes Study Investigators. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007; 49: 194-207
26. Rossert J, Levin A, Roger SD et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 2006; 47: 738-750
27. Galle JC, Claes K, Kiss I et al. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study. Nephrol Dial Transplant 2012; 27: 2303-2311
28. Besarab A, Flaharty KK, Erslev AJ et al. Clinical pharmacology and economics of recombinant human erythropoietin in endstage renal disease: the case for subcutaneous administration. J Am Soc Nephrol 1992; 2: 1405-1416
29. Minutolo R, Chiodini P, Cianciaruso B et al. Epoetin therapy and hemoglobin level variability in non-dialysis CKD patients. Clin J Am Soc Nephrol 2009; 4: 552-559
30. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int 1999; 69: S61-S66
31. Macdougall IC. Iron supplementation in nephrology and oncology: what do we have in common?. Oncologist 2011(Suppl. 3); 16: 25-34
32. Nakanishi T, Hasuike Y, Otaki Y et al. Hepcidin: another culprit for complications in patients with chronic kidney disease? Nephrol Dial Transplant 2011; 26: 3092-3100
33. Johnson DW. Intravenous versus oral iron supplementation in peritoneal dialysis patients. Perit Dial Int 2007; 27(Suppl. 2): S255-S260
34. Macdougall IC. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?. Curr Med Res Opin 2010; 26: 473-482
35. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and metaanalysis. Am J Kidney Dis 2008; 52: 897-906
36. Locatelli F, Aljama P, Canaud B et al., on behalf of the Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) Study. Nephrol Dial Transplant 2010; 25: 2846-2850
37. Moore RA, Gaskell H, Rose P, Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord 2011; 11: 4
38. Spinowitz BS, Kausz AT, Baptista J et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008; 19: 1599-1605
39. Besarab A, Hörl WH, Silverberg D. Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. The Oncologist 2009; 14(Suppl. 1): 22-33
40. Knight TG, Ryan K, Schaefer CP et al. Clinical and economic outcomes in medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: the role of intravenous iron therapy. J Manag Care Pharm 2010; 16: 605-615
41. Minutolo R, Conte G, Cianciaruso B et al. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients. Nephrol Dial Transplant 2012; 27: 2880-2886
42. Hsu CY, Mcculloch CE, Curhan GC. Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol 2002; 13: 2783-2786
43. McClellan W, Aronoff SL, Bolton WK et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20: 1501-1510
44. Fishbane S, Pollack S, Feldman HI et al. Iron indices in chronic kidney disease in the national health and nutritional examination survey 1988-2004. Clin J Am Soc Nephrol 2009; 4: 57-61
45. Portolés J, Gorriz JL, Rubio E et al. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol 2013; 14: 2